logo-loader
viewPhysiomics PLC

Physiomics lands pre-clinical contract for virtual tumour tech

Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division

tumour
Contract wlil be for pre-clinical work

Physiomics Plc (LON:PYC) has been awarded another pre-clinical contract for its Virtual Tumour technology.

The contract is worth £35,000 and with an unnamed major pharma group.

READ: Physiomics and Merck team up to progress Virtual Tumour technology

Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes.

The modelling helps with efficacy and toxicity and identifies the best drug combinations. 

Jim Millen, chief executive, said: "We are delighted to be working with a significant new client.  If this initial project is successful, we would hope to develop a longer-term relationship."

In November, Physiomics completed a  human Virtual Tumour project with Merck following which it signed a master services agreement with the German pharma giant.

Quick facts: Physiomics PLC

Price: 2.8 GBX

AIM:PYC
Market: AIM
Market Cap: £2.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Impax Asset Management reveals key themes investors should...

Impax Asset Management Group PLC (LON:IPX) Head of Client Services and Business Development David Richardson tells Proactive key themes investors should look out for in 2020.  Richardson says he's seeing expansion in developing renewable energy projects in Europe, increased interested in...

22 hours ago

2 min read